ALK and interstitial lung disease: The following factors were considered: age, sex, smoking history, number of pack-years, histological subtype, clinical stage, presence of EGFR/ALK gene abnormalities, type of platinum agent (cisplatin (CDDP) or carboplatin (CBDCA)), concomitant use of bevacizumab (Bev), concomitant use of immune checkpoint inhibitor (ICI), renal function (serum estimated glomerular filtration rate (eGFR) at the start of treatment), and presence of interstitial lung disease.